Interrad Medical, Inc.

Interrad Medical, Inc. specializes in innovative medical devices. Its flagship product, SecurAcath, is designed to securely anchor central venous catheters, significantly improving patient safety and reducing the risks associated with catheter dislodgement. Interrad Medical, Inc.

was founded in 2004 in Plymouth, US, focusing on medical devices aimed at enhancing patient safety in catheter management. The company has executed five funding deals, with the most recent occurring on February 15, 2019, when it raised USD 0. 130 mn in VENTURE DEBT funding. Joe Goldberger serves as the CEO of the organization.

SecurAcath, a product of Interrad Medical, offers a subcutaneous anchor system designed to secure Peripherally Inserted Central Catheters (PICC) and central venous catheters. This innovative device aims to address significant clinical challenges, particularly catheter dislodgement, which poses serious risks, especially for pediatric patients. By utilizing a securement system that minimizes the risk of catheter-related complications such as infections and dislodgements, SecurAcath enhances patient care and reduces the likelihood of hospital readmissions. The product has been implemented in various healthcare settings across North America, including hospitals and outpatient facilities, serving a diverse clientele that includes healthcare providers, nurses, and hospital administrators focused on improving patient safety and operational efficiency.

Interrad Medical's revenue model is rooted in direct sales of its SecurAcath device to healthcare facilities and providers. The company engages in B2B transactions, where hospitals and outpatient treatment centers purchase the securement device as part of their catheter management protocols. This transaction structure allows healthcare organizations to integrate SecurAcath into their existing frameworks to improve patient outcomes and reduce costs associated with catheter-related complications. Pricing strategies for SecurAcath are typically designed to reflect the value of reduced hospital readmissions and improved resource utilization, leveraging the device’s proven efficacy in minimizing complications and associated healthcare costs.

The company positions its flagship product as a necessary tool for modern catheter management, aligning its commercial approach with the needs of its clinical clientele. Interrad Medical, Inc. is focusing on expanding its product line and reaching new markets. Future initiatives include the design and launch of new catheter securement solutions aimed at further enhancing patient safety, with expected releases to be detailed in the coming year.

Additionally, the company is planning to expand its operations into international markets, targeting regions in Europe and Asia by 2025. The recent VENTURE DEBT funding of USD 0. 130 mn will support these initiatives, enabling the company to invest in product development and market entry strategies.